Biotech News
Related news
COCPCocrystal Pharma2026-04-02 12:00 EST
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
SCYXSCYNEXIS2026-01-21 13:00 EST
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
ENTAEnanta Pharmaceuticals2026-06-23 09:10 EST
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
OGENOragenics2026-03-10 12:30 EST
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
SPROSpero Therapeutics2025-12-19 08:00 EST
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
COCPCocrystal Pharma2025-12-18 13:00 EST
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
VIRIVirios Therapeutics2026-04-15 13:00 EST
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
ABUSArbutus2026-07-16 11:30 EST
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
SPROSpero Therapeutics2026-06-17 17:36 EST
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
ABUSArbutus2026-05-13 11:30 EST
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
Arbutus
Hepatitis B Therapeutics Company Arbutus Biopharma develops combination therapies intended to achieve a functional cure for chronic hepatitis B. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins, including surface antigen, and is being studied in combination regimens. Combination...
Recent company news
ABUSArbutus2026-07-16 11:30 EST
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
ABUSArbutus2026-05-13 11:30 EST
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
ABUSArbutus2026-04-15 11:30 EST
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
ABUSArbutus2026-03-23 11:30 EST
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
ABUSArbutus2026-03-03 21:15 EST
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Stock data
- Close
- 4.54 USD
- Market cap
- 841.51M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States